Risperidone and ethyl pyruvate have protective effects against ketamine-induced cognitive impairments in mice
| dc.contributor.author | Kelle, I | |
| dc.contributor.author | Eriman, H. | |
| dc.contributor.author | Erdinc, M. | |
| dc.contributor.author | Uyar, E. | |
| dc.date.accessioned | 2024-08-04T20:51:47Z | |
| dc.date.available | 2024-08-04T20:51:47Z | |
| dc.date.issued | 2022 | |
| dc.department | İnönü Üniversitesi | en_US |
| dc.description.abstract | OBJECTIVE: Ketamine, an N-methyl D-aspartic acid receptor antagonist drug, is reported to produce memory disruptions. The aim of this study was to investigate the protective effects of ethyl pyruvate (EP), a pyruvic acid derivative, and risperidone, an atypical anti-psychotic drug, against ketamine-induced cognitive disturbances. MATERIALS AND METHODS: A passive-avoidance test, a novel object recognition test, and a modified elevated plus maze test were used to assess memory functions. Hippocampal malondialdehyde (MDA) levels were measured to determine the oxidation levels. RESULTS: Ketamine applications produced memory deficits in all tests and insignificantly increased MDA levels, which were alleviated by risperidone, EP, and combination treatments. CONCLUSIONS: Increased oxidative stress and neurotransmission imbalance can be responsible for ketamine-induced memory disruptions. With its antioxidant effects, EP may be helpful to reduce cognitive impairments related to schizophrenia either alone or in combination with antipsychotics. | en_US |
| dc.identifier.endpage | 1716 | en_US |
| dc.identifier.issn | 1128-3602 | |
| dc.identifier.issue | 5 | en_US |
| dc.identifier.pmid | 35302220 | en_US |
| dc.identifier.scopus | 2-s2.0-85126721470 | en_US |
| dc.identifier.scopusquality | Q2 | en_US |
| dc.identifier.startpage | 1708 | en_US |
| dc.identifier.uri | https://hdl.handle.net/11616/100550 | |
| dc.identifier.volume | 26 | en_US |
| dc.identifier.wos | WOS:000771549500037 | en_US |
| dc.identifier.wosquality | Q2 | en_US |
| dc.indekslendigikaynak | Web of Science | en_US |
| dc.indekslendigikaynak | Scopus | en_US |
| dc.indekslendigikaynak | PubMed | en_US |
| dc.language.iso | en | en_US |
| dc.publisher | Verduci Publisher | en_US |
| dc.relation.ispartof | European Review For Medical and Pharmacological Sciences | en_US |
| dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
| dc.rights | info:eu-repo/semantics/closedAccess | en_US |
| dc.subject | Ethyl pyruvate | en_US |
| dc.subject | Risperidone | en_US |
| dc.subject | Ketamine | en_US |
| dc.subject | Schizophrenia | en_US |
| dc.subject | Cognitive symptoms | en_US |
| dc.title | Risperidone and ethyl pyruvate have protective effects against ketamine-induced cognitive impairments in mice | en_US |
| dc.type | Article | en_US |











